Invst LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned 1.00% of Evaxion Biotech A/S as of its most recent SEC filing.
Separately, Armistice Capital LLC boosted its position in shares of Evaxion Biotech A/S by 6.8% in the second quarter. Armistice Capital LLC now owns 392,000 shares of the company’s stock worth $1,137,000 after buying an additional 25,000 shares during the period. Hedge funds and other institutional investors own 11.04% of the company’s stock.
Evaxion Biotech A/S Price Performance
Shares of NASDAQ:EVAX opened at $3.11 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 1 year low of $2.26 and a 1 year high of $13.61. The business has a fifty day simple moving average of $3.01 and a 200 day simple moving average of $3.31. The firm has a market cap of $16.83 million, a price-to-earnings ratio of -0.72 and a beta of -0.27.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research report on Thursday, September 26th.
Read Our Latest Research Report on EVAX
Evaxion Biotech A/S Company Profile
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Featured Articles
- Five stocks we like better than Evaxion Biotech A/S
- Compound Interest and Why It Matters When Investing
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Energy and Oil Stocks Explained
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- 5 Top Rated Dividend Stocks to Consider
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding EVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evaxion Biotech A/S (NASDAQ:EVAX – Free Report).
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.